Originator vs Biosimilar: A Price Comparison by Molecule

It depends on the molecule, not on biosimilars as a category. Indian biosimilars of older cancer biologics are commonly reported at roughly 40 to 75 per cent below the originator's Indian price. Nivolumab's domestic biosimilar was reported at roughly a quarter of the reference price. Four checkpoint inhibitors still have no Indian biosimilar at all.

The single number families are usually given — "biosimilars are about half the price" — holds only for molecules with several competing suppliers. The table below sets out where each one actually stands as of August 2026.

Supportive-care biologics such as filgrastim and pegfilgrastim have had Indian biosimilars for far longer and sit at the wide end of the discount range; they are left off the table because they are not cancer-directed treatment. No comparison of quality between named manufacturers is made or implied anywhere on this page.

On the drug line, and only on the drug line. A biosimilar changes the price of the vial. Day-care admission, nursing time, premedication, pre-cycle blood tests, scans and consultation fees are billed the same either way. On a long course the drug is still the largest single item, which is why one line moving matters so much.

This is why two hospitals can quote different totals while using the same biosimilar. Ask for an itemised quote — drug, day-care, monitoring — rather than one bundled figure, so the brand saving is visible separately from everything around it.

The gap multiplies by the number of cycles, so it is far larger than any per-vial figure suggests. On an illustrative twelve-cycle nivolumab course, indicative published ranges put an originator course at roughly ₹18–34 lakh and a domestic biosimilar course at roughly ₹4–8.5 lakh. Plan against the course, never against one vial.

Cycle count moves the total more than anything else, and it is set by your cancer type, your protocol and how the disease responds — not by budget. An honest full-course figure is therefore a range with its cycle assumption written next to it, which is what a hospital billing desk can give you for your own protocol.

Where a government scheme such as Aarogyasri sets a ceiling for a protocol, that ceiling does not automatically stretch to cover a full course of a higher-cost originator, and insurance sub-limits for injectable oncology drugs differ policy to policy. Take the exact drug and brand your oncologist has proposed to the scheme or insurance desk, and get the applicable ceiling in writing before treatment starts.

This page is for patients and families, especially those weighing a long treatment against limited savings, who want the originator-versus-biosimilar picture across several molecules in one place before a conversation with a hospital billing desk.

It is not a price quote, a suitability check, or a suggestion that you can request a cheaper molecule in place of the one your oncologist has recommended. Which medicines are even valid options for you is decided by your cancer type, stage and biomarker results long before price enters the discussion — and for most patients only one or two of the molecules in the table above are relevant at all. A cheaper drug that is not approved for your diagnosis is not an option, at any price.

Asking whether an approved biosimilar exists for the medicine you have already been prescribed is a different and entirely reasonable question. That is a conversation about brand within the same molecule, and your treating team can answer it directly.

The price reflects a shorter development path, not a lower standard. An Indian biosimilar must show comparable quality, safety and efficacy against the reference product before approval. A comparability programme costs a fraction of an original discovery and trial programme. Domestic manufacture also removes import cost. Competition between suppliers does the rest.

India regulates these products under the similar-biologics pathway overseen by CDSCO with the Department of Biotechnology, first issued in 2012 and revised since. Approval requires analytical, non-clinical and clinical comparability data against the reference product. Some indications are then granted by extrapolation rather than studied again in full — a normal part of the pathway, and worth asking about for your own diagnosis.

India also has no separate interchangeability designation of the kind the United States applies, so which brand you receive is a prescriber decision recorded cycle by cycle, not an automatic pharmacy substitution. If a change is proposed part-way through a course, Switching From an Originator to a Biosimilar Mid-Treatment covers what to ask and what gets documented.

Nothing on this page compares the quality of one named manufacturer's product with another's. The regulatory standard is the same for every approved product listed; brand choice belongs to your treating oncologist.

Pembrolizumab, atezolizumab, durvalumab and ipilimumab, as of August 2026. Nivolumab is the only immune checkpoint inhibitor with a domestically manufactured biosimilar, launched in January 2026 ahead of the originator's Indian patent lapsing in May 2026. Pembrolizumab's protection is expected to begin lapsing around 2028-29. Until then its price is unlikely to move.

The older biologics show what tends to follow. Rituximab was the first cancer biologic to get an Indian biosimilar, in 2007, and the gap widened as more suppliers entered rather than at first launch — Rituximab Biosimilars in India: The Original Cost Story traces that arc. Trastuzumab followed in 2014, bevacizumab a little later, with the same pattern each time.

For a family being quoted for pembrolizumab today, the practical consequence is that waiting is not a plan. Delaying treatment to chase a future price is a clinical decision with real consequences, not a financial one. What exists now is scheme and insurance coverage, an itemised quote, and a frank discussion with your oncologist about whether a molecule that already has a biosimilar is an approved option for your diagnosis.

Because an approved biosimilar is already the cheapest legitimate price for that molecule. Counterfeit checkpoint inhibitors have been reported entering the Indian market around patent and pricing changes. A very large price gap is exactly the environment in which a fake vial finds a buyer. This is patient safety, not caution about a bargain.

Two rules follow, and neither should be softened. These medicines should be dispensed and administered through the treating hospital's own licensed pharmacy — never sourced privately, through an intermediary, or online, however genuine the offer looks. And it is reasonable to ask to see the vial, the batch number, the invoice and the cold-chain record before infusion. That is routine verification, not an accusation.

Cold chain is the part most families never think to check, and it is the part a diverted or repackaged product usually fails — Why Cold Chain Matters for Immunotherapy Medicines explains what correct handling looks like and what a break in it means.

• Rituximab Biosimilars in India: The Original Cost Story — how the first Indian cancer biosimilar moved a molecule's price, and how long it took.
• Switching From an Originator to a Biosimilar Mid-Treatment — what to ask if a brand change is proposed mid-course.
• Why Cold Chain Matters for Immunotherapy Medicines — how these medicines must be stored and transported.
• Immunotherapy Medicines Explained — the index of checkpoint inhibitors, biosimilars and molecule comparisons.
• Immunotherapy at a glance — what this class of treatment does, and what it does not.

Editorial information about a class of medicines — not an offer, a price list, or a recommendation to use any named product, and no comparative quality claim between manufacturers. All pricing, patent and regulatory statements are indicative and dated to August 2026, drawn from published manufacturer announcements, regulatory filings and reported Indian pricing coverage. Whether any of these medicines applies to your treatment, and in which brand, is a decision for your treating oncologist.